Systemic Lupus Erythematosus

SYSTEMIC LUPUS ERYTHEMATOSUS

COVID-19 Vaccines Not Associated With Increased Risk for SLE Flares

The aim of the study was to evaluate the occurrence of SLE flares after COVID-19 vaccination.
Kidney Failure Predictor in Lupus Nephritis Identified

Persistent isolated C3 hypocomplementemia is associated with an increased risk for end-stage kidney disease or death in patients with proliferative lupus nephritis, a study revealed.
Glucocorticoid Tapering Yields Clinical Benefits in Systemic Lupus Erythematosus

Researchers determined the effect of sustained glucocorticoid tapering among patients with SLE.
Initiating Hydroxychloroquine for RA and SLE Does Not Increase Arrhythmia Risk

Researchers studied the association between hydroxychloroquine initiation and risk for incident arrhythmia among patients with rheumatoid arthritis and systemic lupus erythematosus.
Reduction in Swollen, Tender Joints Greater With Litifilimab in Lupus

Patients with SLE receiving litifilimab versus placebo have a greater reduction in the number of swollen and tender joints at 24 weeks.
Elevated Blood Pressure a Sign of Kidney Damage in Lupus Nephritis

Hypertension is prevalent among patients with lupus nephritis, especially in those with proliferative disease, investigators noted.
aGAPSS More Accurate than QRISK3 in Predicting Cardiovascular Risk in SLE

Researchers applied and compared QRISK3 with the adjusted global antiphospholipid syndrome score in patients with systemic lupus erythematosus in order to assess their risk for developing cardiovascular diseases.
Low-Grade Proteinuria May Warrant Biopsy for Lupus Nephritis

Some patients with SLE and low-grade proteinuria may have early active lupus nephritis.
Less Damage Accrual in Lupus Linked to Remission, Low Disease Activity

Researchers evaluated the independent impact of different definitions of remission and low disease activity on damage accrual in systemic lupus erythematosus.
Expert Opinion Correlates With Lupus Low Disease Activity State Definition

Researchers applied the Lupus Low Disease Activity State definition within a large cohort of patients to assess the relationship between it and physician evaluations.

LATEST NEWS

COVID-19 mRNA Vaccine Safe for Patients With Systemic Lupus Erythematosus

Researchers analyzed the association between SARS-CoV-2 vaccination and disease activity and flares in systemic lupus erythematosus.

lupus, rash, systemic lupus erythematosus, SLE

Link Established Between Endogenous Retroviruses and Systemic Lupus Erythematosus

Akiko Iwasaki, PhD, discusses findings of a study she conducted that established a link between endogenous retroviruses and systemic lupus erythematosus.

Immune Responses After COVID-19 Booster Vaccination in Patients With Systemic Autoimmune Diseases

Researchers assessed immune responses among patients with systemic autoimmune diseases following receipt of a COVID-19 vaccine booster dose.

Belimumab Approval Expanded to Include Pediatric Lupus Nephritis

The FDA has expanded the approval of Benlysta (belimumab) to include pediatric patients 5 to 17 years of age with active lupus nephritis.

Population-Based Study Finds Rising Incidence and Prevalence of SLE

Researchers sought to determine the trends in incidence, prevalence, and mortality in patients with systemic lupus erythematosus during a 40-year study period.

Defining “Disease Modification” in SLE: A Step Toward Improving Outcomes

An immunologist proposes a standard definition for “disease modification” in systemic lupus erythematosus to establish treatment targets in clinical trials and clinical practice.

GAPSS Outperforms QRISK in Assessing Cardiovascular Disease Risk in Patients With SLE

Researchers compared the QRISK3 and the adjusted Global AntiPhospholipid Syndrome Score in patients with systemic lupus erythematosus to assess their risk of developing cardiovascular disease.

Breakthrough Infections in Patients With SLE Decreased With COVID-19 Booster Vaccine

For patients with SLE, the risk for breakthrough COVID-19 infection is lower among those who have received a booster vaccine dose.

Cessation of Antimalarial Agents Feasible in Patients With Quiescent SLE

Researchers evaluated the rate of flare in patients with systemic lupus erythematosus who withdrew from antimalarial medications (AM) after achieving disease remission.

Fecal Microbiota Transplant Safe, Effective for Patients With SLE

Researchers evaluated the safety and efficacy of fecal microbiota transplantation for the treatment of patients with systemic lupus erythematosus.

Next post in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

LATEST NEWS

Want to read more?